CD274 and breast carcinoma: Subsequently, using the same assay, atezolizumab plus nab-paclitaxel therapy has been approved for locally advanced breast cancer or mTNBC in cases where the tumor-associated immune cells express PD-L1 with the IC score ≥ 1% [29].